Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

MyCelx Technologies Corporation Director's Dealing 2024

Aug 23, 2024

10837_pos_2024-08-23_ab34ce77-8385-4e31-8476-e42c190a6668.html

Director's Dealing

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

RNS Number : 6160B

MyCelx Technologies Corporation

23 August 2024

23 August 2024

MYCELX Technologies Corporation

("MYCELX" or the "Company") (AIM:MYX)

Director Dealings & Total Voting Rights

MYCELX Technologies Corporation ("MYCELX" or the "Company"), the clean water and clean air technology company established to transform the environmental impact of industry, announces, further to the Placing and Subscription this morning, the following participation by Directors of the Company.

Director Shares held prior to Admission New Shares Purchased Shares held post Admission Percentage of Enlarged Issued Share Capital
Thomas Lamb 325,175 48,836 374,011 1.54%
Connie Mixon1 2,803,944 100,632 2,931,576 12.06%
Andre Schnabl 118,011 48,836 166,847 0.69%

1 Mrs. Mixon's shareholding includes 229,008 shares in the Company held by her spouse.

Total Voting Rights

In conformity with the FCA's Disclosure Guidance and Transparency Rules (the "Rules") provision 5.6.1, the Company would like to notify the market that following Admission on 4 September 2024 its issued share capital will consist of 24,315,271 Common Shares of US$0.025 each.

Shareholders should use 24,315,271 as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Rules.

Terms and definitions used in this announcement shall have the same meaning as ascribed to them in the Proposed Placing and Subscription Announcement released at 7:00 a.m. on 23 August 2024, unless the context requires otherwise.

For further information please contact:

MYCELX Technologies Corporation

Connie Mixon, CEO

Kim Slayton, CFO
Tel: +1 888 306 6843
Canaccord Genuity Limited (Nominated Adviser and Sole Broker)

Henry Fitzgerald-O'Connor

Charlie Hammond
Tel: +44 20 7523 8000
Celicourt Communications (Financial PR)

Mark Antelme

Jimmy Lea

Charlie Denley-Myerson
Tel: +44 20 7770 6424

Notifications of transactions of persons discharging managerial responsibility or connected persons

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

1.   Thomas Lamb

2.   Connie Mixon

3.   Andre Schnabl

2

Reason for the notification

a)

Position/status

1.   Non-Executive Chairman

2.   Chief Executive Officer

3.   Non-Executive Director

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Mycelx Technologies Corporation

b)

LEI

213800UJZINIK2VD1G48

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Common shares of US$0.025

US62847T2024

b)

Nature of the transaction

Purchase of Common Shares

c)

Price(s) and volume(s)

Price(s) Volume(s)
1.   51.5 pence

2.   51.5 pence

3.   51.5 pence
1.   48,836

2.   100,632

3.   48,836

d)

Aggregated information

- Aggregated volume

- Price

N/A

N/A

e)

Date of the transaction

23 August 2024

f)

Place of the transaction

London Stock Exchange

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHGZGZRGFZGDZM